Atopic Dermatitis
From the Journals
Low-dose methotrexate carries higher risk for older patients with CKD
Adverse event data showed an increased risk of myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects.
Latest News
Tapinarof effective for AD in patients as young as 2 years
Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
Latest News
Parent concerns a factor when treating eczema in children with darker skin types
For the parent, the pigmentation changes, rather than the inflammation, might be the governing issue and the reason that he or she brought the...
Latest News
Lebrikizumab gets European nod for treating moderate-to-severe atopic dermatitis
Lebrikizumab remains under review in the United States.
Case Letter
Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease
Dupilumab may provide secondary efficacy in patients with dyshidrotic eczema who also have an eosinophilic condition such as eosinophilic...
Original Research
Impact of the COVID-19 Pandemic on Care for Patients With Atopic Dermatitis
Understanding accessibility to in-person care for patients with atopic dermatitis during the COVID-19 pandemic can assist with the development of...
Latest News
AAD updates guidelines for managing AD with phototherapy and systemic therapies
The work group recommended the inclusion of active comparator arms in randomized, controlled trials as new systemic therapies continue to be...
Latest News
Review estimates acne risk with JAK inhibitor therapy
Acne has been reported to be an adverse effect of JAK inhibitors, but not much is known about how common acne is overall.
Photo Challenge
Pustular Eruption on the Face
A 52-year-old man developed a sudden eruption of small pustules on background erythema and edema covering the forehead, nasal bridge, periorbital...
From the Journals
Dupilumab-associated lymphoid reactions require caution
In cases involving unexpected responses or atypical presentations, clinicians must have a low threshold for stopping dupilumab.
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.